BioFire Diagnostics, F. Hoffman-La Roche Ltd and Luminex Corporation. A DiaSorin Company were dominating the Global Syndromic Multiplex Diagnostic Market in 2021

The Global Syndromic Multiplex Diagnostic Market is expected to grow with the CAGR of 8.7% in the forecast period of 2022 to 2029. The years considered for study are as mentioned below.

Access Full Report @ https://www.databridgemarketresearch.com/reports/global-syndromic-multiplex-diagnostic-market

The syndromic multiplex diagnostic market has witnessed increased strategic developments owing to favourable market scenario.    

The major players dealing in the syndromic multiplex diagnostic market are introducing strong range of products and adopting strategic initiative such as acquisition, agreement into the market. This helped companies to maximize the sales with enhanced product portfolio.

For instance-

  • In March 2021, BioFire Diagnostics (A Subsidiary of biomérieux SA) received the market authorization of BioFire respiratory panel 2.1, a diagnostic test for detecting and identifying multiple respiratory viral and bacterial infections nucleic acids in nasopharyngeal swabs. This has helped the company to commercialize its product

BioFire Diagnostics (A Subsidiary of biomérieux SA) is the dominating player in the syndromic multiplex diagnostic market. The other key players existing in the market includes Luminex Corporation. A DiaSorin Company, F. Hoffmann-La Roche Ltd, BD, Bio-Rad Laboratories, Inc., Cepheid (A Subsidiary of Danaher), QIAGEN, Abbott, Hologic, Inc., Thermo Fisher Scientific Inc., Siemens Healthcare GmbH, Akonni Biosystems, Inc., Biocartis, QuantuMDx Group Ltd., Bosch Healthcare Solutions GmbH (A Subsidiary Of Robert Bosch GmbH), Applied BioCode, Inc., Prominex Inc., Nanōmix, Inc., Curetis (A Subsidiary of OpGen, Inc.), MiRXES Pte Ltd. among others.

BioFire Diagnostics

BioFire Diagnostics (A Subsidiary of biomérieux SA) is headquartered in Utah, U.S. The company is engaged in manufacturing and commercializing of advance systems for syndromic infectious disease diagnostics. The company has product categories FilmArray, Panels.

The company is engaged in continuous development of multiplex diagnosis products.

For instance,

  • In May 2020, BioFire Diagnostics (A Subsidiary of biomérieux SA) received FDA Emergency use authorization for the BIOFIRE RP2.1 panel, which includes 22 pathogens that cause respiratory infections, including SARS-CoV-2 for COVID-19 disease. After this announcement, the company has enhanced their credibility in the market

The company has wide presence across Asia-Pacific, Europe, North America, South America and Middle East & Africa.

F. Hoffmann-La Roche Ltd

F. Hoffmann-La Roche Ltd is headquartered in Basel, Switzerland and was founded in 1896. The company is engaged in the manufacturing and developing of diagnostic products in the areas such as oncology, and dermatology among others. The company is dealing in business segments, that is, Pharmaceutical & Diagnostics in which the market focused segment is Diagnostics. The company has product categories including Pharmaceuticals, Solutions for Diagnostics & Products for Researchers in which the market focused category is Pharmaceuticals.

The company is engaged in continuous development of multiplex diagnosis products.

For instance,

  • In March 2021, F. Hoffmann-La Roche Ltd entered into a definitive merger agreement for Roche to fully acquire GenMark Diagnostics. This has helped the company to increase its portfolio.

The company has wide presence across North America, South America, Europe, Middle East and Africa, Asia-Pacific. The company also has various subsidiary companies such as Roche Holding Ltd (Switzerland), Chugai Pharmaceutical Co., Ltd. (Japan), Roche Algérie SPA (Algeria), mySugr GmbH (Austria) among others.

Luminex Corporation. A DiaSorin Company

Luminex Corporation. A DiaSorin Company has its headquarters in Texas, U.S. was founded in 1995. The company offer a wide range of solutions applicable in diverse markets including clinical diagnostics, pharmaceutical drug discovery, biomedical research, genomic and proteomic research, and food safety. This company has product categories including Instruments & Reagents and Testing & Research in which the market focused categories are Instruments & Reagents.

The company is engaged in continuous development of multiplex diagnosis products.

For instance,

  • In March 2021, Luminex Corporation. A Diasorin Company received FDA Emergency Use Authorization and CE mark for expanded NxTAG respiratory panel test. This approval has helped the company to increase its revenue.

The company has wide presence across North America, Europe, Middle East and Africa.